{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:31:37Z","timestamp":1792704697909,"version":"4.5.0"},"reference-count":18,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2017,8,10]],"date-time":"2017-08-10T00:00:00Z","timestamp":1502323200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck & Co., Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0183023","type":"journal-article","created":{"date-parts":[[2017,8,10]],"date-time":"2017-08-10T13:45:26Z","timestamp":1502372726000},"page":"e0183023","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":67,"title":["Use of the 22C3 anti\u2013PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms"],"prefix":"10.1371","volume":"12","author":[{"given":"Marius","family":"Ilie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirin","family":"Khambata-Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Copie-Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingkang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Juco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,8,10]]},"reference":[{"issue":"21","key":"ref1","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"for the KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non\u2013small-cell lung cancer","volume":"372","author":"EB Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"212289","DOI":"10.7573\/dic.212289","article-title":"Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies","volume":"4","author":"SL Scarpace","year":"2015","journal-title":"Drugs Context"},{"issue":"22","key":"ref3","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1182\/blood-2015-02-567453","article-title":"Immune checkpoint blockade in hematologic malignancies","volume":"125","author":"P Armand","year":"2015","journal-title":"Blood"},{"issue":"10027","key":"ref4","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"RS Herbst","year":"2016","journal-title":"Lancet"},{"key":"ref5","unstructured":"Keytruda [summary of product characteristics]. Hertfordshire, UK: Merck Sharpe &amp; Dohme Limited; 2017."},{"key":"ref6","unstructured":"Keytruda [package insert]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; 2017."},{"issue":"19","key":"ref7","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"for the KEYNOTE-024 Investigators. Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"M Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"ref8","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.5858\/arpa.2015-0542-OA","article-title":"Development of a companion diagnostic for pembrolizumab in non\u2013small cell lung cancer using immunohistochemistry for programmed death ligand-1","volume":"140","author":"M Dolled-Filhart","year":"2016","journal-title":"Arch Pathol Lab Med"},{"issue":"6","key":"ref9","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/PAI.0000000000000408","article-title":"Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non\u2013small-cell lung cancer","volume":"24","author":"C Roach","year":"2016","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"ref10","unstructured":"Ventana Medical Systems Inc. (2017) VENTANA PD-L1 (SP263) Assay. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.ventana.com\/ventana-pd-l1-sp263-assay-2\/\" xlink:type=\"simple\">http:\/\/www.ventana.com\/ventana-pd-l1-sp263-assay-2\/<\/ext-link>."},{"key":"ref11","unstructured":"Dako North American Inc. PD-L1 IHC 22C3 PharmDx. Carpinteria, CA: Dako North America Inc.; 2015."},{"issue":"5","key":"ref12","first-page":"2633","article-title":"Heterogeneity of cell surface antigen expression of human small cell lung cancer detected by monoclonal antibodies","volume":"46","author":"S Fargion","year":"1986","journal-title":"Cancer Res"},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/jamaoncol.2015.3638","article-title":"Quantitative assessment of the heterogeneity of PD-L1 expression in non\u2013small-cell lung cancer","volume":"2","author":"J McLaughlin","year":"2016","journal-title":"JAMA Oncol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/modpathol.2016.186","article-title":"Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer","volume":"30","author":"JA Rehman","year":"2017","journal-title":"Mod Pathol"},{"issue":"5","key":"ref15","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00428-016-1910-4","article-title":"Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients","volume":"468","author":"M Ilie","year":"2016","journal-title":"Virchows Arch"},{"issue":"10","key":"ref16","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/modpathol.2016.117","article-title":"Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas","volume":"29","author":"AH Scheel","year":"2016","journal-title":"Mod Pathol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.jtho.2016.08.146","article-title":"A harmonization study for the use of 22C3 PD-L1 immunohistochemical staining on Ventana&apos;s platform","volume":"11","author":"T Neuman","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"6","key":"ref18","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/PAI.0000000000000534","article-title":"Accurate PD-L1 protocols for non-small cell lung cancer can be developed for automated staining platforms with clone 22C3","volume":"25","author":"R R\u00f8ge","year":"2017","journal-title":"Appl Immunohistochem Mol Morphol"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0186537","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T00:00:00Z","timestamp":1507852800000}}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0183023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T07:55:36Z","timestamp":1589010936000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0183023"}},"subtitle":[],"editor":[{"given":"Giancarlo","family":"Troncone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,8,10]]},"references-count":18,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,8,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0183023","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.17504\/protocols.io.iw9cfh6","asserted-by":"object"},{"id-type":"doi","id":"10.17504\/protocols.io.ixacfie","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,10]]}}}